CareDx reported Q4 2025 revenue of $108 million, up 25% year-over-year, and testing volume of 53,000 tests, up 17%, driving a non-GAAP gross margin of 69%. For full year 2025, revenue reached $380 million, a 14% increase, with testing services at $275 million, digital solutions at $57 million and lab products at $48 million.

The company ended 2025 with $201 million in cash and no debt, and cash collections grew 32% to $406 million, reducing accounts receivable by $23 million and cutting days sales outstanding from 71 to 41. CareDx repurchased $88 million of common stock during the year, including $12 million in Q4 at an average price of $15.16 per share.

CareDx detailed its Transplant+ roadmap to expand into cell therapy monitoring, launching AlloHeme as its first solution. The test identified relapse a median of 41 days before clinical detection, targeting a $1 billion repeat-testing market opportunity in hematopoietic stem cell transplants.

Key 2026 priorities include pipeline advancement, Epic electronic medical record integrations and evidence generation. About 40% of 80% to 85% transplant centers using Epic are bilaterally integrated, delivering a 40% reduction in login issues; the company is also migrating its lab system to support faster launches and data exchange.